eXmoor Pharma

Executive Summary

eXmoor Pharma is a UK-based contract development and manufacturing organization (CDMO) specializing in cell and gene therapies (CGT). Founded in 2017, the company uniquely integrates over two decades of consultancy expertise with full-service CDMO capabilities, offering end-to-end support from CMC strategy and process development to GMP manufacturing and facility design. Serving a global client base of more than 170 biotech innovators, eXmoor focuses on viral vectors, autologous/allogeneic cell therapies, and RNA technologies. Its integrated model allows clients to accelerate development timelines and reduce risks associated with outsourcing complex CGT manufacturing. The CGT CDMO market is growing rapidly, driven by increasing approvals and pipeline expansion. eXmoor is well-positioned to capture market share through its specialized expertise and client-centric approach. The company is expected to benefit from continued outsourcing trends and the need for scalable, high-quality manufacturing capacity. With a strong reputation and strategic location in Bristol, UK, eXmoor is poised for growth, though competition from larger CDMOs remains a challenge.

Upcoming Catalysts (preview)

• Q3 2026Announcement of strategic manufacturing partnership with a top-tier biotech firm70% success
• Q4 2026Completion of a new GMP facility expansion to increase viral vector capacity80% success
• Q2 2026Series A or B funding round to support growth and capacity expansion60% success